Drug firm Zydus Cadila Tuesday said it has received final approval from the Food and Drug Administration of the US to market Atenolol and Chlorthalidone tablets USP. These drugs are used to treat high blood pressure.
The approval has been given to market drugs in two different strengths, the company said in a statement. After getting go-ahead from USFDA, now Chlorthalidone tablets will be marketed in the strengths of 25 mg and 50 mg.
It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
The Zydus group now has 253 product approvals since the commencement of the filing process in 2003-04.
Atenolol belongs to a class of drugs known as beta blockers. It works by blocking the action of certain natural chemicals in the body, such as epinephrine on the heart and blood vessels.
Chlorthalidone is a water pill’ (diuretic) and causes the body to get rid of extra salt and water.
Shares of Cadila Healthcare, the listed entity of the group, was trading at Rs 336.90 per scrip, up 1.26 per cent on BSE.